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carcinoma and 11.2% adenocarcinoma. Degree of differentiation: 37.3% G1–G2 and 37.4% G3. 25.2% Gx. External radiation ther-
apy was administered on pelvic±para-aortic, with parametrial boost if indicated (18.7%). Mean dose 46.7Gy, 1.8Gy/d (34–75). All
patients received chemotherapy with weekly CDDP, 40mg/m2. After treatment, 52.3% achieved complete response while 46.7%
were partial responses. 64 patients (59.8%) were salvaged surgically and 54 (84.4%) receiving brachytherapy later. 30 patients
continued with brachytherapy and 13 with external radiotherapy. Mean and standard deviation for quantitative variables and
absolute frequency and percentage for qualitative variables were obtained. The Kaplan–Meier method was used to estimate
patient survival.
Results. The median duration of follow-up was 39.5 months (7.2–178.6). OS at 3 and 5 years was 78.4% and 64.7% respectively. DFS
in the same periods was 60% and 55.6%. 22.4% patients had local disease recurrence and 25.2% metastases (nodal o visceral). RFS
at 3 and 5 years was 78.8% and 75.1% respectively while MFS was 72.3% and 68.8%. Acute toxicity: urinary, 22.5% G1 and 2.8% G2.
Gastrointestinal: 20.6% G1, 11.2% G2 and 0.9% G3. Late toxicity: urinary, 7.5% G1. Gastrointestinal: 1.8% G1–2.
Conclusion. Our results are similar to other historical series (Claire Vale et al., Meta-analysis). Radiochemotherapy for locally
advances cervical cancer providing good results in DFS and OS with good tolerance and low morbidity.
http://dx.doi.org/10.1016/j.rpor.2013.03.240
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Introduction. Radiation induced SIF is a fracture that results from normal stress applied to weakened bone due to radiotherapy (RT)
in pelvic malignancies. Sacroiliac joint is the most common involved site. Studies have shown a high variability about incidence
(range 3–89%). Latency since radiation to develop a fracture is known to occur between 1 and 190 months. Magnetic Resonance
Imaging (MRI) is currently the method of choice to evaluate SIF due to high sensitiveness. The aim of this article is to describe
SIF risk factors after pelvic RT and the usefulness of MRI technique.
Methods and materials. Data from 13 patients (all females) with pelvic cancer diagnosed as having radiation induced SIF were
reviewed retrospectively. The malignancies included cervical (10), endometrial (1) and rectal cancer (2). Median dose delivered
to whole pelvis was 54Gy (range 44–68). Risk factors including age, postmenopausal stage, diabetes, concurrent chemotherapy,
arterial hypertension and current smoking were recorded. MRI was used to diagnose SIF following RT due to its sensitiveness to
mild changes in bone marrow signal.
Results. Median age of 13 patients was 57 years (range 46–87). Predisposing factors included menopause (13/13), concomitant
chemotherapy (11/13), brachytherapy boost (11/13), current smoking (5/13), arterial hypertension (2/13), diabetes (1/13) and osteo-
porosis (1/13). Most common symptoms were diffuse low back pain radiating to the pelvis and sacral radiculopathy (up to 70%).
The radiological change most frequently seen in SIF was marrow edema. MRI ﬁndings presented as areas of high signal intensity
(SI) on T2 and STIR sequences and low SI on T1.
Conclusions. Pelvic radiotherapy can lead to sacral insufﬁciency fracturesmore likelywhenother comorbidities factors are present.
MRI has became the best imaging method to evaluate SIF in post-treated pelvic malignancies
http://dx.doi.org/10.1016/j.rpor.2013.03.241
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Aim. To evaluate the feasibility of radical radiotherapy after laparoscopic para-aortic lymphadenectomy for staging cervical
carcinoma (CC) patients stages IB-IIIB.
Methods. From March 2009 to December 2012, from 107 patients with CC treated, 62 underwent laparoscopic para-aortic lym-
phadenectomy for staging ﬁrst. Radiotherapy treatment was tailored according the results. External radiation therapy with
concurrent cisplatin (40mg/m2/sem) on cervical tumor and lymph nodes with concomitant para-aortic irradiation in nodes
positive patients, and high dose rate (HDR) brachytherapy boost.
Results. Mean age was 48.05(range, 28–69 years). Average of 13.36 lymph nodes were removed (range 2–34). Ten (16.1%) of 62
patients had metastatic disease in para-aortic nodes and received para-aortic treatment. Mean dose to pelvic volume was 49.5Gy
and 45.24Gy to para-aortic volume. HDR brachytherapy (intrauterine tandem and vaginal colpostates) was delivered in 4–5
fractions of 550–700 cGy. Both radiation procedures were planned with 3D CT guided dosimetry and MRI was used for image-
guided brachytherapy in the last patients.With amean follow-up time of 19months (range 1–43months) actuarial overall survival
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was 93.3% at 19 months and 81.6% estimated at ﬁve years. Disease-free survival at mean follow-up was 89.7% and 74.4% 5 years.
Rectal, urinary and vaginal late toxicity was moderate (CTC grade 2: 5.5%, 5.5% and 17.5% respectively). OS was signiﬁcantly
worse in patients with para-aortic disease compared with those without disease (p<0.000) and in patients with prolonged (>8
weeks) radiation treatment (p=0.022). 25 patients complete QLQ C30, QLQ CX24 and IFSF as measures of quality of life and sexual
function with mean scores of 3.45/4 and 3.07/4 although IFSF mean score was 1.84/5.
Conclusions. Laparoscopic extraperitoneal aortic lymphadenectomy is a feasible procedure, which identify patients with para-
aortic disease tailoring their treatment. The addition of para-aortic external radiation therapy seems to be well tolerated by the
patients, with apparently no inﬂuence in quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.242
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Introduction. The uterine cervical carcinomas remain a health problem with poor survival rates and low rates of local and dis-
tant control. The use of 3D conformal radiotherapy (RTC3D) associated with concomitant chemotherapy (CT) utilizes a same
therapeutic approach all the advantages of a multimodal treatment.
Objective. To perform a descriptive analysis end, a phase II study with QT induction RTC3D/QT and BRT/surgery effort.
Material and methods. Between February 1999 and April 2009 a total of 139 patients diagnosed with uterine cervical carcinoma
were included. The mean age was 58 years (range 29–78). Stage distribution was: IB2 (5.75%), IIA (5.03%), IIB (40.3%), IIIA (2.9%),
IIIB (31.6%), IV (7.91%) and no visceral IVB (6.47%). -Scheme of chemotherapy: a) A CT cycle induction Cisplatin 75mg/m2 and
750mg/m2 Tegafur. Concomitant CT: Cisplatin 25mg/m2 weekly and Tegafur 450mg/m2. - Scheme of Radiotherapy: Virtual
simulation and 3-D planning. The total dose was 45–50.4Gy.
Results. A total of 139 patients were performed until December 2012. With a median follow-up of 110 months (range 46–168
months) are still Alive (49.6%), Exitus (50.4%). Overall survival: by stages: IB2 (62.5%), IIA (85.7%), IIB (67.8%), IIIA (75%), IIIB (27.2%),
IV A (36%), IV B (11.1%). Responses: CR 96 (69.1%), PR 31 (22.3%), ED1 patient (0.7%), PD 1 patient (0.7%), NA (7.2%). Proﬁle of
Recurrence: local (38), regional (37), remote (22), para-aortic note 9. Severe acute toxicity: hematologic 7.9%, gastrointestinal
5.7%, gynecological 2.9%, vascular 4.3%, other 2.9%. Severe chronic toxicity: retroperitoneal ﬁbrosis 4.3%, gastrointestinal 2.9%,
urological 1.4%, other 2.4%. Exitus: 4 patients: In patients surviving longer submitted 9 secondary neoplasms.
Conclusions. The survival for stages IB2 to IIIA is high of 62.5 to 85.7%. In IIIB to IVA is around 36% and 11.1% and the of percetntage
loco – regional recurrence is high. Toxicity is manageable.
http://dx.doi.org/10.1016/j.rpor.2013.03.243
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Purpose. To analyze retrospectively the outcome of patients with cervical cancer treated with external beam radiotherapy (EBR)
and high-dose-rate (HDR) brachytherapy.
Methods and materials. From November 2002 to November 2012, 89 patients with FIGO Stages IB to IVB were treated. The mean
patient age was 53 years. Most frequently used EBR dose to the whole pelvis (with or without paraortic nodes included) was 45Gy
in 25 fractions. Parametrial or bulky lymph node (LN) boost was performed in 11.2% of patients. Brachytherapy with HDR was
performed during EBR or following its completion with ﬁve weekly fractions of 5.5–6Gy to point A. Within the EBR, 79 of the 89
patients (88%) received concomitant chemotherapy (weekly cisplatin: 52 patients or taxol: 27 patients). Patient age, tumor stage,
LN metastases, para-aortic LN sampling and histology were variables analyzed for survival and local control; whereas, doses at
organ risk were variables for analyzing late toxicity. Initially plain X-ray ﬁlm simulation was the standard of care, but further in
time, CT planning was performed. Doses at the rectum and bladder ICRU reference points were calculated for the ﬁrst, and D2cc
bladder, rectum and sigmoid were calculated for the second.
Results. Median follow-up time was 33 months. Three patients had stage I disease (3.3%); 44 stage II disease (49.5%); 32 stage III
disease (36%) and 10 stage IV (11.2%). Five patients (6%) suffered local failure, 5 pelvic nodal failure (6%) and 21 (25%) distant
metastases. Overall survival, disease-free survival, and loco-regional control at 5 years was 68.8%, 59.2%, and 81.9% respectively.
